Veterinary medicine
Masivet®
A targeted therapy dedicated to the management of certain mast cell tumours in dogs.
Overview
A targeted approach in veterinary oncology
Mast cell tumours (MCTs) are the most common cutaneous malignancies in dogs and often have a poor prognosis.
Masivet® is a highly-specific drug, targeting key biological pathways crucial for MCT development and growth.
Masivet® was approved in 2008 by the European Medicines Agency (EMA) in veterinary medicine for the treatment of dog non-resectable MCTs (grade 2 or 3) with presence of a mutated form of the receptor protein c-kit.
Since 2008
Nearly twenty years of commercial use of Masivet®
European authorisation
In 2028, AB Science will celebrate the 20th anniversary of the marketing authorization of Masivet®.
Targeted use
Since its approval, Masivet has been used with success as a targeted approach to cancer management in veterinary medicine and tens of thousands of cases have been treated with Masivet®.
A veterinary advance
Masivet® brought veterinary oncology into the modern era by giving it access to targeted therapies
The Masivet® results in veterinary medicine over the last two decades are promising evidence for the clinical development of this compound in human medicine.